Germany’s flourishing medical cannabis market is now forecast to top €420m this year, according to Prohibition Partners’ upcoming German Cannabis
Germany’s long-anticipated ‘Pillar 2’ is in danger of being abandoned by the government amid ongoing political roadblocks both domestically and
In July, Germany submitted a draft of its Industrial Hemp Liberalization Act, a bill that promises to do away with
Medical cannabis prescriptions have exploded across Germany since April 01 when its landmark CanG Act was brought into force. While
Chill Brands Chill Brands’ ongoing boardroom debacle took another dramatic turn this week following revelations that its ousted directors
Award-winning Frankfurt-based company Bloomwell Group GmbH (“Bloomwell Group”) today announced the launch of Germany’s largest centralised digital platform for medical
On Monday, 4th June 2024, two expert hearings were held regarding the laws ‘to amend the Cannabis Consumption Act and
Written for Business of Cannabis by Prohibition Partners Senior Analyst Alex Khourdaji In the late evening of 16th May 2024, the
A series of proposed amendments to the Cannabis Act (CanG) which would further constrain cultivation associations could be brought in before July 1st. According to a neutral assessment from law firm Witzel Erb Backu & Partner, these amendments may be in violation of the German constitution.
Germany’s highly anticipated ‘Pillar 2’, which would seek to implement a Switzerland-style adult-use cannabis pilot project model, is now being
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
